IRIDEX Corp stock (US4627191006): Ophthalmology device maker with recent market activity
Published on 05/14/2026 at 20:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
IRIDEX Corp shares were recently quoted at $1.03, down 0.96%, according to Google Finance as of May 2026. The company specializes in medical systems for the ophthalmology market, serving US investors through Nasdaq-listed exposure to eye care technology.
As of: 14.05.2026
By the editorial team – specialized in equity coverage.
At a glance
- Name: IRIDEX Corporation
- Sector/industry: Healthcare / Medical Devices
- Headquarters/country: United States
- Core markets: Ophthalmology
- Home exchange/listing venue: Nasdaq (IRIX)
- Trading currency: USD
Official source
For first-hand information on IRIDEX Corp, visit the company’s official website.
Go to the official websiteIRIDEX Corp: core business model
IRIDEX Corp develops, manufactures, and markets laser-based medical systems, delivery devices, and consumables primarily for ophthalmology, as described on Financhill as of 2026. The company's products address treatments for glaucoma, diabetic retinopathy, and retinal disorders, key areas in US eye health markets.
Operations focus on innovative photocoagulation and cyclophotocoagulation platforms, enabling precision in outpatient procedures. This model supports recurring revenue from consumables, appealing to US healthcare providers seeking efficient device solutions.
Main revenue and product drivers for IRIDEX Corp
Core products include Cyclo G6 and IQ lasers, driving revenue through system sales and disposable tips. Ophthalmology consumables form a significant portion, with US clinics as primary customers per company descriptions.
The firm targets growing demand for minimally invasive glaucoma treatments, relevant for US investors tracking medtech trends in aging populations.
Industry trends and competitive position
Ophthalmology devices see rising US demand due to diabetes prevalence, with laser therapies gaining traction for efficacy. IRIDEX Corp positions as a specialist versus broader players like Alcon, focusing on niche laser tech.
Why IRIDEX Corp matters for US investors
Listed on Nasdaq, IRIDEX Corp offers US investors direct access to ophthalmology innovation amid expanding Medicare-covered eye procedures. Its focus aligns with domestic healthcare spending growth.
Read more
Additional news and developments on the stock can be explored via the linked overview pages.
Conclusion
IRIDEX Corp remains focused on ophthalmology lasers amid stable trading around $1.03. US investors note its niche in eye care devices, with market data reflecting sector dynamics. Ongoing developments merit monitoring via official channels.
Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
